Alaunos Therapeutics, Inc. TCRT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-1020.47
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $5,000 | -$4.2M | — | -$3.0M | $2.2M |
| 2024 | $10,000 | -$4.7M | — | -$5.0M | $2.1M |
| 2023 | $5,000 | -$4.7M | — | -$30.3M | $6.3M |
| 2022 | $2.9M | -$37.7M | — | -$29.4M | $38.6M |
| 2021 | $398,000 | -$78.8M | — | -$64.8M | $58.1M |
| 2020 | $0 | -$80.0M | — | -$66.8M | $124.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Weis Holger | Chief Executive Officer | 2026-06-12 | Grant | 7,761 | $2.26 |
| Weis Holger | Chief Executive Officer | 2026-05-22 | Grant | 3,700 | $2.37 |
| Vieser Jaime | director | 2026-04-29 | Grant | 6,515 | $2.59 |
| Postma Robert W | director | 2026-04-29 | Grant | 6,274 | $2.59 |
| Jerman Michael Allen | director | 2026-04-29 | Grant | 6,032 | $2.59 |
| Jerman Michael Allen | director | 2026-01-12 | Grant | 5,406 | $2.89 |
| Postma Robert W | director | 2026-01-12 | Grant | 5,622 | $2.89 |
| Vieser Jaime | director | 2026-01-12 | Grant | 5,839 | $2.89 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1020.47 (distress)
- Working capital / assets 0.396
- Retained earnings / assets -311.74
- EBIT / assets -1.424
- Equity / liabilities 2.648
Source: SEC EDGAR filings · CIK 0001107421 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.